PROF
NASDAQ HealthcareProfound Medical Corp. - common stock
Medical Devices
Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. It operates in Canada, Germany, the United States, China, and Finland. Profound Medical Corp. is headquartered in Mississauga, Canada.
๐ Market Data
| Price | $6.55 |
|---|---|
| Volume | 120,685 |
| Market Cap | 238.01M |
| Beta | 0.530 |
| RSI (14-Day) | 37.1 |
| 200-Day MA | $6.85 |
| 50-Day MA | $7.00 |
| 52-Week High | $8.95 |
| 52-Week Low | $3.76 |
| Forward P/E | -11.14 |
| Price / Book | 4.81 |
๐ฏ Investment Strategy Scores
PROF scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (82/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Institutional Whale (4/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find PROF in your text
Paste any article, transcript, or post โ the tool will extract PROF and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-08-17.